John Neis

Managing Director, Venture Investors LLC

Role: Associate

Site: CDL-Wisconsin

Stream: Risk

John joined Venture Investors of Wisconsin, Inc. in May of 1985 and served as its Vice President and on the Board of Directors. He became a Managing Director of Venture Investors in 1997.

John has extensive experience as a director of portfolio companies, including his current directorships at Cellectar BioSciences, Delphinus Medical Technologies, TAI Diagnostics, Prevacept Infection Control, and Health Scholars. He has experience in assisting companies from inception to public markets. He joined the Board of Third Wave Technologies when they had three employees and served through the initial public offering (they were subsequently acquired by Hologic for $580 million), and he joined the Board of TomoTherapy when they had one employee and served through their public offering, which was the fourth largest healthcare IPO in the first decade of the millennium. Other notable past directorships included NimbleGen Systems, which was acquired by Roche for $272.5 million, and Inviragen, which was acquired by Takeda for up to $250 million.

John has a B.S. in Finance from the University of Utah and an M.S. in Marketing and Finance from the University of Wisconsin. He is a member of the Board of Directors at the Wisconsin Technology Council and the Wisconsin Venture Capital Association, the Board of Trustees of the Morgridge Institute, and the Advisory Boards of the Weinert Applied Ventures in Entrepreneurship (WAVE) in the School of Business and Tandem Press in the School of Education at the University of Wisconsin – Madison.